Metagenomi Therapeutics, Inc. (MGX) has 4 SEC Form 4 insider filings on record in the last 90 days. That includes 1 insider purchase totalling $23K, and 3 sales totalling $5K. Most recent filing: Sept. 11, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 11, 2026 filed Sept. 9, 2026 | Reid Laurence Director | +$23,401 | 20,000 | New | No | |
|
|
||||||
| Sept. 10, 2026 filed Sept. 8, 2026 | Wein Matthew See Remarks | −$415 | 358 | −0% | No | |
|
|
||||||
| Sept. 10, 2026 filed Sept. 8, 2026 | Irish Jian See Remarks | −$2,479 | 2,140 | −1% | No | |
|
|
||||||
| Sept. 10, 2026 filed Sept. 8, 2026 | Wapnick Pamela Chief Financial Officer | −$2,214 | 1,911 | −1% | No | |
|
|
||||||
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free